Armored Chimeric Antigen Receptor T-Cell Therapy Targets Antigen-Heterogeneous Glioma

Through head-to-head in vivo comparisons of potentially synergistic armor combinations, researchers demonstrated that T cells expressing a CAR plus IL12 and the decoy-resistant form of IL18 show strong efficacy against antigen-heterogeneous glioma in immunocompetent mice.